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Background and Purpose—We assessed whether lower-dose alteplase at 0.6 mg/kg is efficacious and safe for acute fluid-
attenuated inversion recovery-negative stroke with unknown time of onset.
Methods—This was an investigator-initiated, multicenter, randomized, open-label, blinded-end point trial. Patients met 
the standard indication criteria for intravenous thrombolysis other than a time last-known-well >4.5 hours (eg, wake-
up stroke). Patients were randomly assigned (1:1) to receive alteplase at 0.6 mg/kg or standard medical treatment if 
magnetic resonance imaging showed acute ischemic lesion on diffusion-weighted imaging and no marked corresponding 
hyperintensity on fluid-attenuated inversion recovery. The primary outcome was a favorable outcome (90-day modified 
Rankin Scale score of 0–1).
Results—Following the early stop and positive results of the WAKE-UP trial (Efficacy and Safety of MRI-Based Thrombolysis 
in Wake-Up Stroke), this trial was prematurely terminated with 131 of the anticipated 300 patients (55 women; mean age, 
74.4±12.2 years). Favorable outcome was comparable between the alteplase group (32/68, 47.1%) and the control group 
Received October 21, 2019; final revision received February 13, 2020; accepted February 25, 2020.
From the Department of Cerebrovascular Medicine (M.K., M. Inoue, S. Yoshimura, M.F.-D., K. Miwa, K. Minematsu, K. Toyoda); Center for 
Advancing Clinical and Translational Sciences (H.Y.), Department of Data Science (K.A., T.H., M.F-D.), Department of Neurology (M. Ihara), and 
Department of Pharmacy (A.O.), National Cerebral and Cardiovascular Center, Suita; Department of Neurology, Graduate School of Medicine, Nippon 
Medical School, Tokyo (J.A., K. Kimura); Department of Stroke Medicine, Institute of Brain and Blood Vessels, Mihara Memorial Hospital, Isesaki 
(T. Kanzawa); Department of Neurosurgery, Yamagata City Hospital Saiseikan (R. Kondo); Department of Neurosurgery, Obihiro Kosei Hospital (M. 
Ohtaki); Department of Stroke Neurology, Kohnan Hospital, Sendai (R.I.); Department of Neurosurgery, Nakamura Memorial Hospital, Sapporo (K. 
Kamiyama); Department of Neurosurgery, Gifu University School of Medicine (T. Iwama); Department of Stroke Science, Research Institute for Brain 
and Blood Vessels, Akita (T.N.); Department of Neurosurgery, Akita University (T.N.); Division of Neurology, Department of Internal Medicine, Saga 
University Faculty of Medicine (Y.Y.); Department of Neurology, Niigata City General Hospital (S.I.); Department of Neurology, Kyoto Second Red 
Cross Hospital (Y.N.); Division of Neurology, Department of Internal Medicine, Tokai University School of Medicine, Isehara (S.T.); Department of 
Cerebrovascular Medicine and Neurology, Cerebrovascular Center, National Hospital Organization Kyushu Medical Center, Fukuoka (Y.O.); Department 
of Neurology, Iwate Prefectural Central Hospital, Morioka (R.D.); Department of Neurology and Strokology, Nagasaki University Graduate School of 
Biomedical Sciences (A.T.); Department of Neurology, Toyota Memorial Hospital (Y.I.); Department of Neurosurgery, Ohnishi Neurological Center, 
Akashi (H.O.); Department of Stroke Medicine, Kawasaki Medical School General Medical Center, Okayama (T. Inoue); Department of Neurosurgery, 
Tokushima University (Y.T.); Department of Neurology, St. Marianna University School of Medicine, Kawasaki (Y.H.); Department of Neurosurgery, 
Kyorin University School of Medicine, Mitaka (Y.S.); Department of Neurosurgery, Kobe City Medical Center General Hospital (N.S.); Department of 
Cerebrovascular Medicine, Stroke Center, Steel Memorial Yawata Hospital, Kitakyushu (M.O.); Department of Neurology, Toranomon Hospital, Tokyo 
(Y.U.); Department of Neurosurgery, Hyogo College of Medicine, Nishinomiya (S. Yoshimura); Department of Neurology, Juntendo University Urayasu 
Hospital (T. Urabe); Department of Strokology, Stroke Center, St. Marianna University Toyoko Hospital, Kawasaki (T. Ueda); Department of Medicine 
and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka (T. Kitazono); Institute for Biomedical Sciences, Iwate Medical 
University, Yahaba (M.S.); and Headquarters of the Iseikai Medical Corporation, Osaka, Japan (K. Minematsu).
Presented in part at the European Stroke Organisation Conference, Milan, Italy, May 22–24, 2019.
The Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.119.028127.
Correspondence to Kazunori Toyoda, MD, Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, 6-1 Kishibe-
Shimmachi, Suita, Osaka 564-8565, Japan. Email toyoda@ncvc.go.jp
© 2020 The Authors. Stroke is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access 
article under the terms of the Creative Commons Attribution Non-Commercial-NoDerivs License, which permits use, distribution, and reproduction in any 
medium, provided that the original work is properly cited, the use is noncommercial, and no modifications or adaptations are made.
Thrombolysis With Alteplase at 0.6 mg/kg for  
Stroke With Unknown Time of Onset
A Randomized Controlled Trial
Masatoshi Koga, MD; Haruko Yamamoto, MD; Manabu Inoue, MD; Koko Asakura, PhD;  
Junya Aoki, MD; Toshimitsu Hamasaki, PhD; Takao Kanzawa, MD; Rei Kondo, MD;  
Masafumi Ohtaki, MD; Ryo Itabashi, MD; Kenji Kamiyama, MD; Toru Iwama, MD;  
Taizen Nakase, MD; Yusuke Yakushiji, MD; Shuichi Igarashi, MD; Yoshinari Nagakane, MD;  
Shunya Takizawa, MD; Yasushi Okada, MD; Ryosuke Doijiri, MD; Akira Tsujino, MD;  
Yasuhiro Ito, MD; Hideyuki Ohnishi, MD; Takeshi Inoue, MD; Yasushi Takagi, MD;  
Yasuhiro Hasegawa, MD; Yoshiaki Shiokawa, MD; Nobuyuki Sakai, MD; Masato Osaki, MD;  
Yoshikazu Uesaka, MD; Shinichi Yoshimura, MD; Takao Urabe, MD; Toshihiro Ueda, MD;  
Masafumi Ihara, MD; Takanari Kitazono, MD; Makoto Sasaki, MD; Akira Oita, BS;  
Sohei Yoshimura, MD; Mayumi Fukuda-Doi, MD; Kaori Miwa, MD; Kazumi Kimura, MD;  
Kazuo Minematsu, MD; Kazunori Toyoda , MD;  
for the THAWS Trial Investigators




 http://ahajournals.org by on February 11, 2021
Koga et al  Low-Dose Intravenous Alteplase in Wake-Up Stroke  1531
(28/58, 48.3%; relative risk [RR], 0.97 [95% CI, 0.68–1.41]; P=0.892). Symptomatic intracranial hemorrhage within 22 
to 36 hours occurred in 1/71 and 0/60 (RR, infinity [95% CI, 0.06 to infinity]; P>0.999), respectively. Death at 90 days 
occurred in 2/71 and 2/60 (RR, 0.85 [95% CI, 0.06–12.58]; P>0.999), respectively.
Conclusions—No difference in favorable outcome was seen between alteplase and control groups among patients with 
ischemic stroke with unknown time of onset. The safety of alteplase at 0.6 mg/kg was comparable to that of standard 
treatment. Early study termination precludes any definitive conclusions.
Registration—URL: https://www.clinicaltrials.gov; Unique identifier: NCT02002325.   
(Stroke. 2020;51:1530-1538. DOI: 10.1161/STROKEAHA.119.028127.)
Key Words: control groups ◼ informed consent ◼ intracranial hemorrhages ◼ magnetic resonance imaging  
◼ stroke, acute ◼ tissue-type plasminogen activator
Recently, the WAKE-UP trial (Efficacy and Safety of MRI-Based Thrombolysis in Wake-Up Stroke) revealed 
the efficacy and safety of alteplase (a recombinant plasmin-
ogen activator) at 0.9 mg/kg guided by a mismatch between 
diffusion-weighted imaging (DWI) and fluid-attenuated in-
version recovery (FLAIR; negative FLAIR pattern or DWI-
FLAIR mismatch) in patients with acute ischemic stroke with 
an unknown time of onset.1 In Japan, a different alteplase 
dose of 0.6 mg/kg is only available for patients with acute 
ischemic stroke based on a single-arm trial, observational 
studies, and guidelines.2–5 The ENCHANTED (Enhanced 
Control of Hypertension and Thrombolysis Stroke Study) re-
vealed that small difference of efficacy and overall similarity 
regarding the balance between efficacy and safety between 0.9 
and 0.6 mg/kg of alteplase though this trial did not reach its 
primary end point of noninferiority.6 Herein, we describe the 
THAWS trial (Thrombolysis for Acute Wake-Up and Unclear-
Onset Strokes With Alteplase at 0.6 mg/kg; www.Clinical 
Trials.gov, Identifier: NCT02002325; UMIN clinical trial 
ID: UMIN000011630), which was conducted to test whether 
alteplase at 0.6 mg/kg is effective and safe in patients with 
acute ischemic stroke with an unknown time of onset who had 
acute ischemic lesions on DWI and no marked corresponding 
hyperintensity on FLAIR.7
Methods
THAWS was an investigator-initiated, multicenter, randomized, open-
label, blinded-end point evaluation, controlled trial involving patients 
with an unknown time of stroke onset. The design was similar to that 
of the WAKE-UP trial. We did not use placebo mainly due to the 
financial limitation. All patients met the clinical criteria for intrave-
nous thrombolysis in Japan,5 other than a time last-known-well >4.5 
hours. Patients could undergo randomization if MRI showed a nega-
tive FLAIR pattern (Figure I in the Data Supplement) with standard 
settings on FLAIR based on the imaging guidelines provided by the 
WAKE-UP group.
The trial was approved by the local ethics committee or insti-
tutional review board at each participating center. Patients or their 
relatives provided written informed consent according to ethical 
regulations.
Investigators are listed in the Data Supplement. A Steering 
Committee was responsible for the design, interpretation, and super-
vision of the trial.
The trial was overseen by an independent data and safety moni-
toring board. No efficacy interim analysis was conducted, but one 
safety interim analysis with an initial 150 patients was planned. 
The Research Electronic Data Capture system was used to collect 
trial data. The authors confirmed the accuracy and completeness of 
the data and adverse event reporting and the fidelity of the trial to 
the protocol.
De-identified individual participant data may be available upon 
request, only if the request is intended to contribute to the improve-
ment of people’s health and welfare.
Additional information is described in the Data Supplement.
Patients
Patients with stroke symptoms on awaking or with unknown 
time of onset were eligible if they presented >4.5 hours since 
last-known-well and within 4.5 hours after symptom recog-
nition were 20 years or older and had a premorbid modified 
Rankin Scale (mRS) (Table I in the Data Supplement). We ini-
tially set an upper time limit of 12 hours after last-known-well 
in May 2014 and revised this to no time limit in August 2015 
to match this eligibility criterion with that of the WAKE-UP 
trial. Patients were excluded if they had mild stroke with 
National Institutes of Health Stroke Scale (NIHSS; ranging 
from 0 to 42, with higher score indicating more severe stroke) 
<5 (revised to <2 in August 2015 due to the same reasons 
given above) or severe stroke with NIHSS >25 in contrast to 
no lower and upper limit of NIHSS in the WAKE-UP trial. 
Otherwise, patients fulfilled the standard eligibility criteria for 
the use of alteplase (Table I in the Data Supplement).5 Patients 
underwent MRI examination with DWI, FLAIR, T2*, and 
time-of-flight magnetic resonance angiography of the circle 
of Willis. The details of DWI and FLAIR parameters, which 
have been described previously,7 were matched to those used 
in the WAKE-UP trial. Patients underwent randomization if 
they showed mismatch between the presence of an abnormal 
signal on DWI and no marked signal change on FLAIR (neg-
ative FLAIR pattern) in the corresponding region of the acute 
stroke. Patients with clinically acute ischemic stroke and 
a negative FLAIR pattern who did not display an abnormal 
signal on DWI were also enrolled. A detailed imaging guide-
book provided by the WAKE-UP steering committee included 
extensive examples illustrating the inclusion and exclusion 
criteria for MRI. Patients were excluded if they had any con-
traindications for MRI (eg, cardiac pacemaker), were planned 
or anticipated to undergo treatment with surgery or endovas-
cular reperfusion strategies, were pregnant, lactating, or po-
tentially pregnant, or had a life expectancy of 6 months or less 
according to the judgment of an investigator. As MRI criteria, 
patients were excluded with intracranial hemorrhage or large 
infarct with Alberta Stroke Program Early CT Score of 4 or 
less in the territory of the middle cerebral artery, or with visual 
lesion volume over 50% of the anterior cerebral artery or pos-
terior cerebral artery, more than half of the brain stem or more 
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Randomization and Treatment
Eligible patients were randomized in a 1:1 ratio to receive ei-
ther intravenous alteplase (alteplase group) or standard treat-
ment (control group), based on a minimization scheme with 
stratification by severity of symptoms as assessed using the 
NIHSS score (≤11 or >11) though those in the WAKE-UP trial 
were done by the NIHSS (≤10 or >10) and by age (≤60/>60 
years). Treatment was allocated by an in-house, validated, 
interactive email-based system, right after a patient was 
enrolled by an investigator from the study site. Both patients 
and investigators were aware of treatment allocation. Primary 
and secondary outcomes were assessed without information 
regarding treatment allocation by independent and certified 
neurologists, neurosurgeons, nurses, or clinical research coor-
dinators. Just after randomization, patients randomized to the 
alteplase group were treated with intravenous alteplase at 0.6 
mg/kg (with 10% bolus administration and 90% by 60-mi-
nute infusion) within 4.5 hours of waking up or discovery, 
and those randomized to the control group were treated with 
the standard treatment using 1 to 3 antithrombotic drugs, in-
cluding oral aspirin (160–300 mg/day), oral clopidogrel (75 
mg/day), intravenous argatroban, or intravenous unfraction-
ated heparin, but excluding the combination of argatroban and 
heparin, according to decisions of the attending physician. 
All antithrombotics were basically prohibited for use in the 
alteplase group within the initial 25 hours. Treatment was ini-
tiated as soon as possible within 60 minutes after MRI exam-
ination. Thrombolytic agents such as urokinase, monteplase, 
and tenecteplase (unavailable in Japan) were prohibited dur-
ing the 90-day study period in both groups.
Clinical and Imaging Assessment
Certified neurologists, neurosurgeons, nurses, or clinical re-
search coordinators performed clinical assessments at base-
line, at 22 to 36 hours, at 7 to 14 days, or at hospital discharge 
(if earlier), and at 90 days after randomization. At 90 days, 
mRS and adverse events were blindly assessed without in-
formation on treatment assignment by an independent phy-
sician, nurse, or clinical research coordinator. Brain MRI was 
performed at baseline, at 22 to 36 hours to identify intracra-
nial hemorrhage, and at 7 to 14 days to delineate final infarct 
volume. The details of clinical and imaging assessments and 
major protocol violation are described in the Data Supplement.
Outcome Measures
The primary efficacy end point was favorable outcome, de-
fined as mRS score of 0 to 1 at 90 days after stroke onset. 
Secondary efficacy end points were category shift in mRS 
score at 90 days after stroke onset, mRS score 0 to 2 at 90 days 
after stroke onset, category shift in NIHSS score at 24 hours 
after initiation of treatment, and category shift in NIHSS score 
at 7 days after initiation of treatment. Imaging outcomes (ex-
ploratory end points) included recanalization of the culprit ar-
tery on magnetic resonance angiography at 22 to 36 hours after 
initiation of treatment, infarct volume on FLAIR at 7 days and 
infarct growth as defined by infarct volume on FLAIR at 7 
days minus infarct volume on DWI at baseline. Recanalization 
was defined by modified Mori grade 3.8
Safety end points were symptomatic intracranial hemor-
rhage (sICH) at 22 to 36 hours and major extracranial bleed-
ing9 and death due to any cause at 90 days. The definition of 
sICH was an increase in NIHSS score by ≥4 from baseline and 
parenchymal hematoma type II on MRI at 22 to 36 hours after 
initiation of treatment.
Statistical Analysis
We determined the sample size on the basis of the primary end 
point. A total of 278 patients was required to ensure 1−β=90% 
probability to demonstrate that the relative effect of intrave-
nous alteplase compared with standard treatment for ischemic 
stroke patients is more than a fraction of 0.5 of the combined 
relative effect of intravenous alteplase across the stroke throm-
bolysis studies,10–13 by using a 1-sided χ2 test of significance 
level of 2.5%, where the effects of intravenous alteplase and 
standard treatment are assumed to be 30% and 20% commonly 
for Japanese patients and comparable combined studies. We 
planned to recruit a total of 300 patients, accounting for pos-
sible treatment failures, protocol violations, and dropouts.
Statistical analyses are elaborated in a prespecified statis-
tical analysis plan. Primary analyses were undertaken accord-
ing to an intention-to-treat principle. A secondary per-protocol 
analysis excluded patients with major protocol violations. We 
also performed an as-treated analysis to assess whether the 
intention-to-treat basis analysis resulted in any underestima-
tion of the treatment effect. The details of missing data man-
agement and primary, secondary, safety data, and subgroup 
analyses are described in the Data Supplement.
A value of P<0.05 based on a 2-sided test was consid-
ered significant. Primary and secondary end points and pre-
defined subgroup analyses mentioned above were performed 




Following the early stop and positive results of the WAKE-UP 
trial, the THAWS steering committee suspended further enroll-
ments on July 10, 2018. From May 1, 2014 to July 10, 2018, 
a total of 465 patients underwent screening at 40 centers. Of 
these, 352 were excluded, including 207 who had no mismatch 
between findings on DWI and FLAIR or had intracerebral 
hemorrhage and 45 for whom thrombectomy was planned 
(Figure 1). A total of 131 patients underwent randomization, as 
compared with the targeted enrollment of 300 patients.
Of the 131 enrolled patients, 70 were assigned to the 
alteplase group and 61 to the control group (Figure 1). 
Baseline demographic and clinical characteristics in both 
groups are shown in Table 1. Median NIHSS score at the time 
of baseline examination was 7 for each group. Wake-up stroke 
was found in 53 patients (75.7%) in the alteplase group and 40 
patients (65.6%) in the control group. Median time between 
last-known-well and symptom recognition was 7.0 hours for 
each group. Median interval between last-known-well and 
randomization was 10.0 hours for each group.
All patients in the alteplase group and 1 patient in the control 
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just after bolus infusion due to subdural hematoma on baseline 
FLAIR in one patient from the alteplase group. Thus, 71 patients 
who received alteplase and 60 patients who received standard 
treatment were included in the safety analysis set. Three patients 
in the alteplase group and 4 patients in the control group showed 
protocol violation (alteplase group: one patient with alteplase 
infusion before randomization, one with subdural hematoma, 
and one with endovascular treatment; control group: one pa-
tient with elevated level of activated partial thromboplastin time, 
one with acute antiplatelet therapy with cilostazol, one with hy-
poglycemia and one treated with alteplase) and one patient in 
the alteplase group was lost to follow-up. Four patients in the 
alteplase group and 4 in the control group underwent 3-month 
follow-up assessment outside of the allowance schedule or with 
an unblinded assessor. Details of acute treatments from ran-
domization to 24 hours are summarized in Table II in the Data 
Supplement. Any antithrombotic therapy, oral antiplatelet, and 
intravenous anticoagulant therapies were performed in 85%, 
49%, and 66%, respectively, in the control group, compared with 
13%, 9%, and 6%, respectively, in the alteplase group according 
to the protocol.
Efficacy Outcomes
Favorable outcomes at 90 days after stroke onset were compa-
rable between the alteplase group (47.1%) and control group 
(48.3%; RR, 0.97 [95% CI, 0.68–1.41]; P=0.892; Table 2; 
Figure 2). Sensitivity analyses using the full analysis data set, 
per-protocol data analysis, and as-treated analysis showed 
similar results (Table 2).
An mRS score of 0 to 2 at 90 days after stroke onset was 
also comparable between the alteplase group (58.8%) and con-
trol group (60.3%; RR, 0.97 [95% CI, 0.73–1.30]; P=0.862; 
Table 2; Figure 2). No difference in category shift in NIHSS 
score was seen at 24 hours and at 7 days after the initiation 
of treatment between groups. Regarding imaging outcomes, 
early recanalization of the culprit artery was more frequent in 
the r-tPA group as compared with the control group though 
the number of patients involved in this analysis (n=41) was 
relatively small. There was no significant difference in infarct 
volume and infarct growth between the 2 groups.
In prespecified subgroup analyses of the primary end 
point, a significant interaction was apparent between treat-
ment groups and premorbid antithrombotic medication 
(Figure 3). In patients with premorbid antithrombotic medi-
cation, favorable outcome was more frequent in the alteplase 
group though the number of patients (n=40) was small. 
In additional subgroup analyses of the primary end point, 
patients with NIHSS ≥5, those who had culprit arterial occlu-
sion, those with baseline Alberta Stroke Program Early CT 
Score on DWI <10, or those with acute ischemic lesion on 
24-hour FLAIR in the alteplase group tended to show a higher 
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percentage of favorable outcome as compared with those in 
the control group, although no significant differences were ev-
ident (Figure 3).
Safety Outcomes
In the safety analysis set, sICH at 22 to 36 hours occurred in 
one of 71 patients (1.4%) in the alteplase group and none of 
60 patients in the control group (RR, infinity [95% CI, 0.06 
to infinity]; P>0.999; Table 3). No patients experienced major 
extracranial bleeding in either group (Table 3). Two of the 
70 patients (2.8%) in the alteplase group and 2 of 61 patients 
(3.3%) in the control group died within 90 days (RR, 0.85 
[95% CI, 0.06–12.58]; P>0.999) (Table 3). Causes of death 
were heart failure in 1 patient each for both groups, gastric 
cancer in another patient in the control group, and unknown 
in another patient in the alteplase group who showed sudden 
death. In the alteplase group, 9 patients (12.7%) experienced a 
serious adverse event, as compared with 6 patients (10%) in the 
control group (P=0.632). Detailed lists of any and serious ad-
verse events are provided in Table III in the Data Supplement.
Discussion
We compared intravenous thrombolysis with alteplase at 0.6 
mg/kg against standard medical treatment in patients with 
stroke symptoms on waking or with unknown time of onset 
who had no clearly visible signal change on FLAIR. No dif-
ference in the proportion of favorable outcome as defined 
by mRS score 0 to 1 was evident between the alteplase and 
standard treatment groups. Early termination with the small 
sample size precluded definitive conclusions. Regarding the 
safety profile, the proportion of sICH and that of death did 
not differ between groups. Therefore, the safety of intravenous 
alteplase at 0.6 mg/kg was comparable to standard treatment 
in acute ischemic stroke on waking or with unknown time of 
onset who showed a negative FLAIR finding.
A well-designed single-arm trial (MR-WITNESS) and a 
randomized controlled trial (WAKE-UP) both tested alteplase 
at 0.9 mg/kg in patients with acute ischemic stroke with un-
known time of onset.1,14 The proportion of favorable outcome 
at 3 months after onset in our alteplase group (47.1%) was 
comparable to results from MR WITNESS (43.5% in patients 
with premorbid mRS score 0–1) and WAKE-UP (53.3%). 
Median NIHSS in the alteplase group was similar among the 3 
clinical trials, at 7 (IQR, 4–13) in this trial, 7.5 (IQR, 4.3–13.8) 
in MR WITNESS, and 6 (IQR, 4–9) in WAKE-UP.1,14 Efficacy 
of alteplase at 0.6 mg/kg thus may not be inferior to that at 0.9 
mg/kg. Regarding the safety profile, the proportion of sICH 
in the alteplase group was 1.4% (SITS-MOST criteria: paren-
chymal hematoma type II with deterioration in NIHSS score 
by ≥4) in this trial, 1.3% (ECASS III criteria: any intracranial 
hemorrhage with deterioration in NIHSS score by ≥4) in MR 
WITNESS, and 2.0% (SITS-MOST criteria) in WAKE-UP. 
Mortality at 3 months in the alteplase group was 2.8% in 
this trial, 8.8% in MR WITNESS, and 4.1% in WAKE-UP. 
Because the negative FLAIR pattern indicates that ischemic 
stroke occurred within the preceding 4.5 hours,15,16 MRI-based 
patient selection using the FLAIR negative pattern is a reason-
able method offering acceptable safety profiles.
On the other hand, the proportion of favorable outcome at 
3 months after onset in the control group (48.3%) appeared 
high as compared with that of WAKE-UP (41.8%). The pro-
portion of sICH in the control group was 0% in this trial and 
0.4% in WAKE-UP. The mortality rate in the control group 
was 3.3% in this trial and 1.2% in WAKE-UP. Somewhat sur-
prisingly, about half of the patients with acute ischemic stroke 
with unknown time of onset and negative FLAIR finding 
showed mRS score 0 to 1 at 3 months.






Age, y; mean±SD 73.2±12.4 75.8±11.9
Female sex, n (%) 25 (36) 30 (49)
Medical history, n (%)
  Hypertension 49 (70) 41 (67)
  Diabetes mellitus 14 (20) 12 (20)
  Dyslipidemia 23 (33) 23 (38)
  Atrial fibrillation 27 (39) 21 (34)
  History of ischemic stroke/TIA 8 (11) 14 (23)
Reasons for unknown time of symptom onset, n (%)
  Sleep 53 (76) 40 (66)
  Other* 17 (24) 21 (34)
NIHSS score, median (IQR)† 7 (4–13) 7 (5–12)
Vessel occlusion site on MRA, n (%)
  Any 19 (27) 22 (36)
  Internal carotid artery 1 (1) 2 (3)
  Middle cerebral artery (M1) 6 (9) 8 (13)
  Middle cerebral artery (M2) 11 (16) 11 (18)
  Posterior cerebral artery 1 (1) 0
  Basilar artery 0 1 (2)
DWI-ASPECTS, median (IQR) 9 (8–10) 9 (8–10)
Lesion volume of DWI, mL; 
median (IQR)
3.5 (0.8–14.2) 1.9 (0.3–11.1)
Time from last-known-well to 
symptom recognition, median 
(IQR), h
7 (5.5–9) 7 (5.5–9)
Time from symptom recognition 
to MRI, median (IQR), h
2.0 (1.5–2.8) 2.0 (1.5–2.8)
Time from start of MRI to 
randomization, median (IQR), min
52.0 (35.7–70.3) 44.1 (33.0–62.4)
Time from symptom recognition 
to randomization, median (IQR), h
3.1 (2.4–3.7) 2.9 (2.3–3.8)
Time from last-known-well to 
randomization, median (IQR), h
10.2 (8.2–12.2) 10.3 (7.7–11.8)
DWI indicates diffusion-weighted imaging; DWI-ASPECTS, Alberta Stroke 
Program Early CT Score on DWI; IQR, interquartile range; MRA, magnetic 
resonance angiography; MRI, magnetic resonance imaging; NIHSS, National 
Institutes of Health Stroke Scale; and TIA, transient ischemic attack.
*Symptom onset was unknown due to aphasia, coma, dementia, or other.
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Better than expected outcome for the control group seems 
to be caused by the open treatment design that allows early 
initiation of antithrombotic therapy within the initial 24 hours. 
Antithrombotic therapy was initiated in 13% of alteplase-
treated patients versus 85% of control patients within the ini-
tial 24 hours (Table II in the Data Supplement). In particular, 
dual antiplatelet therapy became common among patients 
with acute noncardioembolic stroke after publication of the 
CHANCE trial (Clopidogrel in High-Risk Patients with Acute 
Nondisabling Cerebrovascular Events) and a meta-analy-
sis;17,18 the therapy was initiated in 3% of alteplase-treated 
patients versus 23% of control patients within the initial 24 
hours, such intergroup changes were not present in the blinded 
treatment trials though direct evidence of better outcomes with 
dual antiplatelet therapy was not reported. Another reason for 
better than expected outcomes in both alteplase and control 
groups were that the efficacy and safety of acute mechanical 
thrombectomy were established in 2015.19 During the regis-
tration period of the THAWS trial, adding mechanical throm-
bectomy therapy became standard treatment for all kinds of 
acute ischemic stroke. Thereafter, patients with major artery 
occlusion were often excluded at the initial assessment and 
Table 2. Primary and Secondary Efficacy and Imaging Outcomes
Outcome Alteplase Group (n=70) Control Group (n=61) Effect Variable Value (95% CI)* P Value
Primary efficacy end point
  Favorable outcome at 90 d—n/N  
(%, 95% CI)†
32/68 (47.1, 34.8–59.6) 28/58 (48.3, 35.0–61.8) Relative risk 0.97 (0.68–1.41) 0.89
Secondary efficacy end points
  Median score on modified Rankin Scale at 
90 d (IQR)‡
2 (1–3) 2 (0–3) Common odds ratio 0.88 (0.47–1.63) 0.67
  modified Rankin Scale score 0–2 at 90 
d—n/N (%, 95% CI)
40/68 (58.8, 46.2–70.6) 35/58 (60.3, 46.6–73.0) Relative risk 0.97 (0.73–1.30) 0.86
  Categorical shift in NIHSS score at 24 h 
after initiation of treatment from baseline, 
mean±SD (n)
−2.6±4.2 (70) −2.8±3.9 (61) Estimated difference 0.1 (−1.2 to 1.5) 0.85
  Categorical shift in NIHSS score at 7 d 
after initiation of treatment from baseline, 
mean±SD (n)
−3.3±7.4 (68) −4.3±4.2 (60) Estimated difference 0.8 (−1.2 to 2.7) 0.44
Imaging end points
  Recanalization of culprit artery on MRA at 
22–36 h
14/19 (73.7) 9/22 (40.9) Relative risk 1.80 (1.02–3.64) 0.04
  Infarct volume on FLAIR at 7 d, mL; 
mean±SD (n)
23.7±36.6 (66) 28.2±46.7 (60) Estimated difference −4.5 (−19.2 to 10.3) 0.55
  Infarct growth on FLAIR at 7 d, mL; 
mean±SD (n)
14.6±28.7 (66) 18.1±34.5 (60) Estimated difference −3.5 (−14.6 to 7.7) 0.54
Sensitivity analyses
  Primary efficacy end point including patients who had 3-mo assessment with unblinded assessor
   Favorable outcome at 90 d—n/N (%)† 33/70 (47.1) 29/61 (47.3) Relative risk 0.99 (0.69–1.42) 0.52
  Primary efficacy end point analyzed by a marginal model with linearization-based method
   Favorable outcome at 90 d— n/N (%)† 32/66 (48.5) 28/57 (48.8) Odds ratio 0.97 (0.48–1.97) 0.32
  Primary efficacy end point analyzed with multiple imputation method
   Favorable outcome at 90 d—n/N (%)† 32/66 (48.5) 28/57 (48.8) Odds ratio 1.17 (0.54–2.54) 0.70
Per-protocol analysis
  Primary efficacy end point excluding patients who had major protocol violation
   Favorable outcome at 90 d—n/N (%)† 32/66 (48.5) 27/53 (50.9) Relative risk 0.95 (0.66–1.37) 0.79
As-treated analysis
  Primary efficacy end point
   Favorable outcome at 90 d—n/N (%)† 32/69 (46.4) 28/57 (49.1) Relative risk 0.94 (0.65–1.36) 0.76
FLAIR indicates fluid-attenuated inversion recovery; IQR, interquartile range; MRA, magnetic resonance angiography; and NIHSS, National Institutes of Health 
Stroke Scale.
*Relative risks, common odds ratios, and differences are for the alteplase group, as compared with the control group.
†A favorable outcome was defined as a modified Rankin Scale score 0 or 1 (full scale ranges from 0 [no symptoms] to 6 [death]) at 90 d.
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instead taken to the catheterization laboratory. For this reason, 
patient enrollment was slower than expected and neurolog-
ical severity of enrolled patients shifted to milder population. 
The greater the proportion of patients with mild stroke symp-
toms involved, the smaller the difference in effect between 
alteplase and standard treatments that might be achieved, as 
shown by the recent PRISM trial.20 Patients with mild stroke 
symptoms were likely to have had lacunar infarcts. In the sec-
ondary post hoc analysis of the WAKE-UP trial showed no 
better effect in outcome with alteplase.21 Finally, three-fifths 
of enrolled patients did not show magnetic resonance angiog-
raphy-confirmed arterial occlusion. The frequency of arterial 
recanalization was somewhat high in the alteplase group 
(75%) as compared in the control group (58%), this would not 
have influenced overall outcomes.
Recently, the EXTEND trial (Extending the Time for 
Thrombolysis in Emergency Neurological Deficits) re-
vealed the efficacy of thrombolysis between 4.5 and 9 hours 
after onset of stroke with a nonsignificant tendency toward 
an increase in sICH.22 EXTEND tested thrombolysis with 
alteplase at 0.9 mg/kg in patients with ischemic stroke, in-
cluding wake-up stroke with significant penumbral mis-
match on computed tomography or MRI. ECASS4, which 
was a similar trial to EXTEND,  did not show the efficacy of 
Figure 2. Distribution of scores on 90-d modi-
fied Rankin Scale (intention-to-treat population).
Figure 3. Prespecified (A) and additional (B) subgroup analyses: relative risks and 95% CIs for favorable outcome. ASPECTS indicates Alberta Stroke 
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thrombolysis, probably due to the small number of patients.23 
In contrast to the EXTEND and ECASS4 trials, which in-
volved patients with penumbral imaging mismatch mainly 
due to major artery occlusion, the THAWS trial involved 
many patients without major artery occlusion and who were 
thus likely to have had small-vessel disease. The WAKE-UP 
and MR-WITNESS trials might have had the same problem, 
in that patients with moderate to severe stroke may have 
joined the trial less frequently because of the predominant 
performance of thrombectomy. However, this problem might 
have most strongly influenced our trial due to the later reg-
istration period.
The strength of this trial was the identical imaging and 
clinical criteria to the WAKE-UP trial; this would make the 
comparison of results between the 2 trials straightforward. 
The baseline DWI lesion volume was similar to that of the 
WAKE-UP trial. Of the 131 patients, 39 had a baseline DWI 
Alberta Stroke Program Early CT Score of 10 followed by 9 
cases with no lesions seen on FLAIR at 7 days. Although these 
cases showed certain neurological deficits (median NIHSS 5 
for both), and even blurry equivocal lesions did not meet the 
measures of Alberta Stroke Program Early CT Score, some of 
these cases might have represented stroke mimics.
Some limitations to this trial need to be considered. First, 
the premature termination of the trial resulted in a smaller 
number of patients than planned. The second key limitation 
was the open treatment design, which might have affected the 
treatment process during the observational period. Third, the 
exclusion to perform mechanical thrombectomy may have 
caused a selection bias. Finally, the present dose of alteplase 
(0.6 mg/kg) differed from that used in the WAKE-UP and 
MR-WITNESS trials. This difference might make comparison 
among trials difficult.
Conclusions
No difference in favorable outcome was seen between alteplase 
and control groups in patients with unknown time of stroke 
onset and negative FLAIR findings. In contrast, we confirmed 
the safety of alteplase at 0.6 mg/kg in these patients. The trial 
seemed to include many patients with small-vessel disease 
that had no large artery occlusion, for which early initiation 
of aggressive antithrombotic treatment might be effective as 
compared with thrombolysis.
Collaborative analyses with similar trials are planned to 
assess effective treatments in patients with unknown time of 
stroke onset.
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